CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

LOS ANGELES–(BUSINESS WIRE)–CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (“KemPharm”). KemPharm is a specialty biopharmaceutical company focused on the discovery and development of novel treatments…